Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ABSI Stock Forecast 2025-2026
$3.58
Current Price
$538.33M
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ABSI Price Targets
+179.3%
To High Target of $10.00
+151.4%
To Median Target of $9.00
+62.0%
To Low Target of $5.80
ABSI Price Momentum
+12.9%
1 Week Change
-0.3%
1 Month Change
+15.1%
1 Year Change
+36.6%
Year-to-Date Change
-43.4%
From 52W High of $6.33
+78.1%
From 52W Low of $2.01
📊 TOP ANALYST CALLS
Did ABSI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Absci is one of their latest high-conviction picks.
Latest ABSI Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, ABSI has a bullish consensus with a median price target of $9.00 (ranging from $5.80 to $10.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $3.58, the median forecast implies a 151.4% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Vamil Divan at Guggenheim, projecting a 179.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ABSI Analyst Ratings
9
Buy
0
Hold
0
Sell
ABSI Price Target Range
Low
$5.80
Average
$9.00
High
$10.00
Current: $3.58
Latest ABSI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ABSI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 13, 2025 | Needham | Gil Blum | Buy | Maintains | $7.00 |
| Oct 2, 2025 | JP Morgan | Brian Cheng | Overweight | Initiates | $N/A |
| Aug 18, 2025 | Morgan Stanley | Vikram Purohit | Overweight | Maintains | $5.89 |
| Aug 13, 2025 | Needham | Gil Blum | Buy | Maintains | $8.00 |
| Jul 28, 2025 | Morgan Stanley | Vikram Purohit | Overweight | Maintains | $6.40 |
| May 14, 2025 | Needham | Gil Blum | Buy | Reiterates | $9.00 |
| Apr 16, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $9.00 |
| Apr 9, 2025 | Needham | Gil Blum | Buy | Reiterates | $9.00 |
| Mar 20, 2025 | Guggenheim | Vamil Divan | Buy | Reiterates | $10.00 |
| Mar 19, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $7.00 |
| Mar 19, 2025 | Needham | Gil Blum | Buy | Reiterates | $9.00 |
| Jan 22, 2025 | Needham | Gil Blum | Buy | Initiates | $9.00 |
| Jan 17, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $7.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $7.00 |
| Jan 8, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jan 8, 2025 | Keybanc | Overweight | Maintains | $N/A | |
| Dec 13, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 3, 2024 | Guggenheim | Vamil Divan | Buy | Reiterates | $10.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $7.00 |
| Oct 2, 2024 | Guggenheim | Vamil Divan | Buy | Initiates | $10.00 |
Absci Corporation (ABSI) Competitors
The following stocks are similar to Absci based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Absci Corporation (ABSI) Financial Data
Absci Corporation has a market capitalization of $538.33M with a P/E ratio of -3.8x. The company generates $2.82M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -77.8% quarter-over-quarter, while maintaining an operating margin of -7,977.2% and return on equity of -55.7%.
Valuation Metrics
Market Cap
$538.33M
Enterprise Value
$392.08M
P/E Ratio
-3.8x
PEG Ratio
0.2x
Price/Sales
191.2x
Growth & Margins
Revenue Growth (YoY)
-77.8%
Gross Margin
N/A
Operating Margin
-7,977.2%
Net Margin
0.0%
EPS Growth
-77.8%
Financial Health
Cash/Price Ratio
+28.3%
Current Ratio
5.9x
Debt/Equity
3.0x
ROE
-55.7%
ROA
-30.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Absci Corporation (ABSI) Business Model
About Absci Corporation
What They Do
Biotechnology company specializing in drug discovery.
Business Model
Absci Corporation leverages artificial intelligence and synthetic biology to expedite the discovery and development of therapeutic proteins. By utilizing a proprietary platform that integrates machine learning, the company generates revenue through partnerships and collaborations in the pharmaceutical industry, focusing on creating more efficient drug development processes.
Additional Information
Located in Vancouver, Washington, Absci aims to transform the biopharmaceutical sector by providing scalable and innovative solutions that promise faster and more cost-effective delivery of medicines. The company's cutting-edge approach positions it as a key player in the global healthcare and life sciences markets.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
156
CEO
Mr. Sean McClain
Country
United States
IPO Year
N/A
Website
www.absci.comAbsci Corporation (ABSI) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study
Absci Corporation stock jumps after initiating dosing in its phase I/IIa ABS-201 study for androgenetic alopecia, seeking early safety and efficacy signals.
Dec 05, 2025
By Zacks Equity Research
Analyst Blog
Latest News
Absci Corporation (ABSI) Presents at Jefferies London Healthcare Conference 2025 Transcript
15 days ago
Quick Summary
Absci Corporation (ABSI) will present at the Jefferies London Healthcare Conference on November 18, 2025, featuring CEO Sean McClain and CFO Zach Jonasson.
Why It Matters
Absci Corporation's presentation at a major healthcare conference may signal potential developments or insights that could impact stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Absci Corporation (ABSI) will hold its Q3 2025 earnings call on November 12, 2025, featuring key executives and participants from several financial institutions.
Why It Matters
The upcoming Q3 earnings call for Absci Corporation presents an opportunity for investors to assess financial performance and strategic direction, impacting stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Absci Corporation (Nasdaq: ABSI) reported interim Phase 1 results for ABS-101 and plans to initiate a Ph1/2a trial for ABS-201 in December, expanding its strategy to include endometriosis. Sufficient cash to fund operations into mid-2028.
Why It Matters
Absci Corporation's clinical trial advancements and strong cash position signal potential growth and stability, appealing to investors seeking opportunities in biotech innovation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Absci Corporation (ABSI) reported a quarterly loss of $0.20 per share, slightly worse than the estimated loss of $0.19, but an improvement from a loss of $0.24 per share a year prior.
Why It Matters
Absci's larger-than-expected loss signals potential challenges in its financial performance, which may impact investor confidence and stock valuation moving forward.
Source: Zacks Investment Research
Market Sentiment:
Negative
Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025
1 month ago
Quick Summary
Absci (Nasdaq: ABSI) will report its Q3 2025 business updates and financial results on November 12, 2025, after market close.
Why It Matters
Absci's upcoming financial results could impact stock performance, reflecting its progress in biotech and AI advancements, influencing investor sentiment and market valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Absci Corporation (Nasdaq: ABSI) will participate in upcoming investor conferences, focusing on its development of therapeutics using generative AI.
Why It Matters
Absci Corporation's participation in investor conferences signals potential for increased visibility and engagement, which may drive interest and investment in its innovative AI-driven therapeutics.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ABSI Stock
What is Absci Corporation's (ABSI) stock forecast for 2026?
Based on our analysis of 14 Wall Street analysts, Absci Corporation (ABSI) has a median price target of $9.00. The highest price target is $10.00 and the lowest is $5.80.
Is ABSI stock a good investment in 2026?
According to current analyst ratings, ABSI has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.58. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ABSI stock?
Wall Street analysts predict ABSI stock could reach $9.00 in the next 12 months. This represents a 151.4% increase from the current price of $3.58. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Absci Corporation's business model?
Absci Corporation leverages artificial intelligence and synthetic biology to expedite the discovery and development of therapeutic proteins. By utilizing a proprietary platform that integrates machine learning, the company generates revenue through partnerships and collaborations in the pharmaceutical industry, focusing on creating more efficient drug development processes.
What is the highest forecasted price for ABSI Absci Corporation?
The highest price target for ABSI is $10.00 from Vamil Divan at Guggenheim, which represents a 179.3% increase from the current price of $3.58.
What is the lowest forecasted price for ABSI Absci Corporation?
The lowest price target for ABSI is $5.80 from at , which represents a 62.0% increase from the current price of $3.58.
What is the overall ABSI consensus from analysts for Absci Corporation?
The overall analyst consensus for ABSI is bullish. Out of 14 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $9.00.
How accurate are ABSI stock price projections?
Stock price projections, including those for Absci Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 6, 2025 4:25 PM UTC